US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Trump Says Anthropic No Longer Seen as National Security Threat 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the Oppenheimer & Co., Inc. 26th Annual Healthcare Conference in New York City on December 8, 2015 at 9:45 a.m. EST.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in Boston and New York, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com.
KERYX CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
